Nuwellis Receives USPTO Notice Of Patent Allowance For Innovative Pediatric CRRT Technology
Portfolio Pulse from Benzinga Newsdesk
Nuwellis, Inc. (NASDAQ:NUWE) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to its pediatric Continuous Renal Replacement Therapy (CRRT) device, Vivian™. This patent enhances Nuwellis' intellectual property portfolio and supports the development of technology aimed at improving treatment for critically ill children. The technology allows for seamless switching between stationary and mobile operation modes, enhancing patient mobility. The development of a new pediatric CRRT device is underway, funded partly by a $1.7 million NIH grant, in collaboration with Koronis Biomedical Technologies Corporation.
May 02, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuwellis has been granted a patent for its pediatric CRRT device, indicating progress in its pediatric care technology and potential market advantage.
The receipt of a patent allowance from the USPTO for Nuwellis' pediatric CRRT device represents a significant step forward in the company's development of specialized medical technology. This patent not only strengthens Nuwellis' intellectual property portfolio but also sets the stage for the company to develop and market its innovative pediatric CRRT device, potentially leading to increased market share and revenue in the specialized field of pediatric care. The partnership with Koronis Biomedical Technologies Corporation and the support from a NIH grant further validate the potential and importance of this technology, suggesting a positive outlook for Nuwellis' growth and investment in pediatric healthcare solutions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100